



**SDI Review Form 1.6**

**PART 1:**

Journal Name:	<b><u>British Journal of Pharmaceutical Research</u></b>
Manuscript Number:	<b>2013_BJPR_5761</b>
Title of the Manuscript:	<b>IN SILICO OPTIMIZED MECHLORETHAMINE BASED DRUG STRUCTURES TARGETING BRAIN AND SPINAL CORD TUMORS</b>
Type of the Article	<b>Research Paper</b>

**General guideline for Peer Review process is available in this link:**

**<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>**

- This form has total 7 parts. Kindly note that you should use all the parts of this review form.



**SDI Review Form 1.6**

**PART 2: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Compulsory</b> REVISION comments	<p>Text is confused, paragraphs lack any sort of continuity. E.g. the following two paragraphs lack coherence:</p> <p>“Types of childhood brain and spinal cord tumors include: astrocytomas, atypical teratoid tumor, brain stem glioma, CNS embryonal tumor, CNS germ cell tumor, craniopharyngioma, ependymoma, medulloblastoma, spinal cord tumors, and supratentorial primitive neuroectodermal tumors.</p> <p>Mechlorethamine (mustine, mustargen, chlorethazine, chlormethine) is a nitrogen mustard agent having antineoplastic and immunosuppressive activity. Mechlorethamine alkylates DNA, especially at the 7-Nitrogen site of guanine, which induces interstrand crosslinking and inhibition of DNA repair. It is a light yellow brownish, hygroscopic, crystalline powder that is very soluble in water and alcohol. There are approximately 20,000 new cases of primary CNS tumors in the United States every year [1]. Growth of the CNS tumors is at the considerable expense of other structure contained within the CNS, therefore symptoms depend on the location of tumor [1]. Symptoms include: confusion,</p>	



**SDI Review Form 1.6**

	headache, nausea, vomiting papilledema, seizures, and cognitive impairment [1].” A literary reference for medulloblastoma therapy is outdated-published in 1988. In current treatment other therapies are used.	
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments	I am not able to assess the quality of English because it is not my native language, I recommend checking by native speaker.	

**Note: Anonymous Reviewer**